Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose

Cancer Immunology, Immunotherapy

Volumn 61, Issue 6, 2012, Pages 817-826

  Lövgren, Tanja ^a   Baumgaertner, Petra ^a   Wieckowski, Sébastien ^a   Devêvre, Estelle ^a   Guillaume, Philippe ^a   Luescher, Immanuel ^a   Rufer, Nathalie ^a   Speiser, Daniel E ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Human CD8 + T cells; Melanoma; Peptide dose for vaccination; Tumor antigen Melan A MART 1

Indexed keywords

AGATOLIMOD; FREUND ADJUVANT; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MELAN A; MONTANIDE ISA 51; PERFORIN; T LYMPHOCYTE RECEPTOR; TETRAMER;

ARTICLE; BINDING AFFINITY; CANCER IMMUNIZATION; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DEGRANULATION; DRUG MEGADOSE; DRUG MIXTURE; EX VIVO STUDY; FEMALE; HUMAN; LOW DRUG DOSE; LYMPHOCYTE CLONE; LYMPHOCYTE DIFFERENTIATION; MALE; MELANOMA; PRIORITY JOURNAL; PROTEIN SECRETION; T LYMPHOCYTE ACTIVATION; UPREGULATION;

CANCER VACCINES; CHEMOTHERAPY, ADJUVANT; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HLA-A2 ANTIGEN; HUMANS; MALE; MART-1 ANTIGEN; MELANOMA; NEOPLASM STAGING; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 84862308565     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1140-1     Document Type: Article

References (47)

1. Jaeger E, Bernhard H, Romero P, Ringhoffer M, Arand M, Karbach J, Ilsemann C, Hagedorn M, Knuth A (1996) Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 66(2):162-169. doi:10.1002/(SICI)1097-0215(19960410)66:2<162:AID-IJC4>3.0.CO;2-0 (Pubitemid 26248194)
2. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM (1997) Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 3(1):37-44
3. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P (2005) Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115(3): 739-746. doi:10.1172/JCI23373 (Pubitemid 40322250)
4. Speiser DE, Romero P (2010) Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol 22(3):144-154. doi:10.1016/j.smim.2010.03.004
5. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, Liu C, Lesokhin AM, Sahawneh D, Zhong H, Panageas KS, Perales MA, Altan-Bonnet G, Wolchok JD, Houghton AN (2009) Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 206(4): 849-866. doi:10.1084/jem.20081382
6. Venturi V, Price DA, Douek DC, Davenport MP (2008) The molecular basis for public T-cell responses? Nat Rev Immunol 8(3):231-238. doi:10.1038/nri2260 (Pubitemid 351323289)
7. Derby M, Alexander-Miller M, Tse R, Berzofsky J (2001) High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL. J Immunol 166(3):1690-1697 (Pubitemid 32114651)
8. Alexander-Miller MA, Leggatt GR, Berzofsky JA (1996) Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 93(9):4102-4107 (Pubitemid 26144250)
9. Bennett MS, Ng HL, Dagarag M, Ali A, Yang OO (2007) Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J Virol 81(10):4973-4980. doi: 10.1128/JVI.02362-06 (Pubitemid 46744409)
10. Speiser DE, Kyburz D, Stubi U, Hengartner H, Zinkernagel RM (1992) Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation or cytotoxicity to peptide-coated target cells but not for in vivo protection. J Immunol 149(3):972-980
11. Zeh HJ 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC (1999) High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162(2):989-994 (Pubitemid 29035425)
12. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD (1999) Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol 162(4):2227-2234 (Pubitemid 29288845)
13. Sedlik C, Dadaglio G, Saron MF, Deriaud E, Rojas M, Casal SI, Leclerc C (2000) In vivo induction of a high-avidity, high-frequency cytotoxic T-lymphocyte response is associated with antiviral protective immunity. J Virol 74(13):5769-5775 (Pubitemid 30412943)
14. Belyakov IM, Kuznetsov VA, Kelsall B, Klinman D, Moniuszko M, Lemon M, Markham PD, Pal R, Clements JD, Lewis MG, Strober W, Franchini G, Berzofsky JA (2006) Impact of vaccine-induced mucosal high-avidity CD8+ CTLs in delay of AIDS viral dissemination from mucosa. Blood 107(8):3258-3264. doi: 10.1182/blood-2005-11-4374
15. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, Asher TE, Samri A, Schnuriger A, Theodorou I, Costagliola D, Rouzioux C, Agut H, Marcelin AG, Douek D, Autran B, Appay V (2007) Superior control of HIV-1 replication by CD8? T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 204(10):2473-2485. doi:10.1084/jem.20070784 (Pubitemid 47529331)
16. Neveu B, Debeaupuis E, Echasserieau K, le Moullac-Vaidye B, Gassin M, Jegou L, Decalf J, Albert M, Ferry N, Gournay J, Houssaint E, Bonneville M, Saulquin X (2008) Selection of high-avidity CD8 T cells correlates with control of hepatitis C virus infection. Hepatology 48(3):713-722. doi:10.1002/hep.22379
17. Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, Pantaleo G (2006) Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol Rev 211:236-254. doi:10.1111/j.0105-2896.2006.00395.x (Pubitemid 43882976)
18. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 105(51):20410-20415. doi:10.1073/pnas.0810114105
19. Appay V, Douek DC, Price DA (2008) CD8+ T cell efficacy in vaccination and disease. Nat Med 14(6):623-628. doi:10.1038/nm.f.1774 (Pubitemid 351809548)
20. Harty JT, Badovinac VP (2008) Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol 8(2):107-119. doi:10.1038/nri2251 (Pubitemid 351161304)
21. Bullock TN, Mullins DW, Engelhard VH (2003) Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. J Immunol 170(4):1822-1829 (Pubitemid 36197398)
22. Hamilton SE, Harty JT (2002) Quantitation of CD8+ T cell expansion, memory, and protective immunity after immunization with peptide-coated dendritic cells. J Immunol 169(9):4936-4944 (Pubitemid 35217159)
23. Kochenderfer JN, Chien CD, Simpson JL, Gress RE (2007) Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpGoligodeoxynucleotides. ClinImmunol 124(2):119-130. doi:10.1016/j.clim.2007.04.003 (Pubitemid 47059037)
24. Narayan S, Choyce A, Fernando GJ, Leggatt GR (2007) Secondary immunisation with high-dose heterologous peptide leads to CD8 T cell populations with reduced functional avidity. Eur J Immunol 37(2):406-415. doi:10.1002/eji.200535688 (Pubitemid 46915580)
25. Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, Yuan L, Chisari FV, Furze J, Bartholomeuz R et al (1995) Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest 95(1):341-349. doi:10.1172/JCI117662
26. Audran R, Lurati-Ruiz F, Genton B, Blythman HE, Ofori-Anyinam O, Reymond C, Corradin G, Spertini F (2009) The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial. PLoS One 4(10):e7304. doi:10.1371/journal.pone.0007304
27. Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Gotz M, Funk I, Ringhoffer M, Bunjes D, Hofmann S, Ritter G, Dohner H, Schmitt M (2010) High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 95(7):1191-1197. doi:10.3324/haematol.2009.014704
28. Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V, Tauber E, Frisch J, Manns MP (2008) Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 134(5):1385-1395. doi:10.1053/j.gastro. 2008.02.058
29. Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS (2006) Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.Vaccine 24(20):4343-4353. doi:10.1016/j.vaccine.2006.03.009
30. Speiser DE, Baumgaertner P, Barbey C, Rubio-Godoy V, Moulin A, Corthesy P, Devevre E, Dietrich PY, Rimoldi D, Lienard D, Cerottini JC, Romero P, Rufer N (2006) A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 177(2):1338-1348 (Pubitemid 44036641)
31. Wieckowski S, Baumgaertner P, Corthesy P, Voelter V, Romero P, Speiser DE, Rufer N (2009) Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol 183(8):5397-5406. doi:10.4049/jimmunol.0901460
32. Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC, Romero P (1999) High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 190(5): 705-715 (Pubitemid 29428652)
33. AltmanJD,MossPA,GoulderPJ,BarouchDH,McHeyzer-Williams MG, Bell JI, McMichael AJ, DavisMM(1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274(5284):94-96
34. Purbhoo MA, Boulter JM, Price DA, Vuidepot AL, Hourigan CS, Dunbar PR, Olson K, Dawson SJ, Phillips RE, Jakobsen BK, Bell JI, Sewell AK (2001) The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J Biol Chem 276(35):32786-32792
35. Pittet MJ, Rubio-Godoy V, Bioley G, Guillaume P, Batard P, Speiser D, Luescher I, Cerottini JC, Romero P, Zippelius A (2003) Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells. J Immunol 171(4):1844-1849 (Pubitemid 36966467)
36. Rufer N, Reichenbach P, Romero P (2005) Methods for the ex vivo characterization of human CD8+ T subsets based on gene expression and replicative history analysis. Methods Mol Med 109:265-284
37. Wonderlich J, Shearer G, Livingstone A, Brooks A (2006) Induction and measurement of cytotoxic T lymphocyte activity, Chapter 3, Unit 3.11. Curr Protoc Immunol. doi:10.1002/0471142735.im0311s72
38. Speiser DE, Migliaccio M, Pittet MJ, Valmori D, Lienard D, Lejeune F, Reichenbach P, Guillaume P, Luscher I, Cerottini JC, Romero P (2001) Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cells. Eur J Immunol 31(2):459-466. doi: 10.1002/1521-4141(200102)31:2<459::AID-IMMU459>3.0.CO;2-Y (Pubitemid 32166600)
39. Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM, Corthesy P, Devevre E, Speiser DE, Rufer N (2007) Four functionally distinct populations of human effector-memory CD8+ T lymphocytes. J Immunol 178(7):4112-4119 (Pubitemid 46492360)
40. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281(1-2):65-78 (Pubitemid 37324571)
41. Makedonas G, Banerjee PP, Pandey R, Hersperger AR, Sanborn KB, Hardy GA, Orange JS, Betts MR (2009) Rapid up-regulation and granule-independent transport of perforin to the immuno-logical synapse define a novel mechanism of antigen-specific CD8+ T cell cytotoxic activity. J Immunol 182(9):5560-5569. doi:10.4049/jimmunol.0803945
42. Powell DJ Jr, Rosenberg SA (2004) Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination. J Immunother 27(1):36-47
43. Maile R, Siler CA, Kerry SE, Midkiff KE, Collins EJ, Frelinger JA (2005) Peripheral "CD8 tuning" dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo. J Immunol 174(2):619-627 (Pubitemid 40094253)
44. Park JH, Adoro S, Lucas PJ, Sarafova SD, Alag AS, Doan LL, Erman B, Liu X, Ellmeier W, Bosselut R, Feigenbaum L, Singer A (2007) 'Coreceptor tuning': cytokine signals transcriptionally tailor CD8 coreceptor expression to the self-specificity of the TCR. Nat Immunol 8(10):1049-1059. doi:10.1038/ni1512 (Pubitemid 47430446)
45. Alexander-Miller MA (2005) High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors. Immunol Res 31(1):13-24. doi:10.1385/IR:31:1:13 (Pubitemid 40065421)
46. Xiao Z, Mescher MF, Jameson SC (2007) Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activation. J Exp Med 204(11):2667-2677. doi:10.1084/jem.20062376 (Pubitemid 350044790)
47. Johansen P, Storni T, Rettig L, Qiu Z, Der-Sarkissian A, Smith KA, Manolova V, Lang KS, Senti G, Mullhaupt B, Gerlach T, Speck RF, Bot A, Kundig TM (2008) Antigen kinetics determines immune reactivity. Proc Natl Acad Sci USA 105(13):5189-5194. doi:10.1073/pnas.0706296105 (Pubitemid 351738532)